Triple PPI therapy approved for new H pylori uses in Japan
This article was originally published in Scrip
Executive Summary
Several companies have received regulatory approval in Japan for the concomitant use of their proton pump inhibitors (PPIs) as part of combination therapy for the eradication of Helicobacter pylori infections in three new medical settings.